Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients

• Status: Unknown status
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the synergistic anti-tumor effect of ChangTai Keli based on chemotherapy for colon cancer patients by a randomized, parallel-group, double-blind, multicenter clinical study.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing NingQi Medicine Science and Technology Co., Ltd.
• Collaborator: Jiangsu Province Hospital of Traditional Chinese Medicine

Criteria

Inclusion Criteria:

1. collaboration from hospital oncology patients in hospital. Confirmed by pathology or cytology for colon cancer, Ⅱ A - Ⅳ period of patients with colon cancer line (or late postoperative palliative chemotherapy).

2. age > 18 years of age, and the 75 - year - old patient or less;

3. fitness score (ECOG PS) 2 minutes or less, expected lifetime > 6 months;

4. volunteered for the clinical research, and sign the informed consent.

Exclusion Criteria:

1. patients with other primary malignant tumors within 1 year;

2. intentional, severe liver and kidney disease patients with serious obstacle and function;

3. pregnancy or lactation women, mental disorders to cooperate to complete the healer;

4. is in other subjects or attended other drugs test interval < 3 months.

5. do not meet the inclusion criteria;